---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-233375"
form_type: "8-K"
ticker: "COAG"
cik: "0002114044"
company_name: "Hemab Therapeutics Holdings, Inc."
filed_at: "2026-05-21T11:05:12+00:00"
generated_at: "2026-05-21T11:13:37.365237+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Hemab reports Q1 net loss $22.7M; completes $346.7M IPO, gets BTD for sutacimig

## Summary
- Net loss Q1 2026: $22.7M ($23.98/share) vs $15.3M ($16.18/share) YoY.
- Cash $163.5M at March 31; with $317.2M net IPO proceeds, runway into 2029.
- Completed IPO in May 2026: 19.26M shares at $18.00, raising $346.7M gross; now listed on Nasdaq under COAG.
- FDA granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia in March 2026.
- Preparing Phase 3 pivotal trial for sutacimig in GT expected H2 2026; data from Factor VII and VWD trials in late 2026/early 2027.

## SEC filing metadata
- accession: 0001193125-26-233375
- form_type: 8-K
- ticker: COAG
- cik: 0002114044
- company_name: Hemab Therapeutics Holdings, Inc.
- filed_at: 2026-05-21T11:05:12+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2114044/000119312526233375/0001193125-26-233375-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2114044/000119312526233375/d102408d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-233375
- JSON: https://secwatch.observer/filing/0001193125-26-233375.json
- Plain text: https://secwatch.observer/filing/0001193125-26-233375.txt

## Key facts
- Earnings Releases
  Hemab Therapeutics Holdings, Inc. reported the first quarter ended March 31, 2026 results: net income $22.7 million, or $23.98 per share, EPS $23.98 per share.
  - Period: the first quarter ended March 31, 2026
  - Net income: $22.7 million, or $23.98 per share
  - EPS: $23.98 per share
  - Result: reported results
  source text: Hemab Therapeutics Holdings, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2114044/000119312526233375/0001193125-26-233375-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.